Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Candel Therapeutics (CADL) Equity Average (2020 - 2023)

Candel Therapeutics' Equity Average history spans 4 years, with the latest figure at $26.9 million for Q3 2023.

  • For Q3 2023, Equity Average fell 52.06% year-over-year to $26.9 million; the TTM value through Sep 2023 reached $26.9 million, down 52.06%, while the annual FY2022 figure was $55.9 million, 175.66% up from the prior year.
  • Equity Average for Q3 2023 was $26.9 million at Candel Therapeutics, down from $35.2 million in the prior quarter.
  • Across five years, Equity Average topped out at $63.9 million in Q1 2022 and bottomed at -$35.3 million in Q2 2021.
  • The 4-year median for Equity Average is $35.2 million (2023), against an average of $24.4 million.
  • The largest annual shift saw Equity Average surged 466.32% in 2022 before it tumbled 52.06% in 2023.
  • A 4-year view of Equity Average shows it stood at -$19.2 million in 2020, then skyrocketed by 431.24% to $63.6 million in 2021, then fell by 21.46% to $49.9 million in 2022, then plummeted by 46.12% to $26.9 million in 2023.
  • Per Business Quant, the three most recent readings for CADL's Equity Average are $26.9 million (Q3 2023), $35.2 million (Q2 2023), and $43.7 million (Q1 2023).